- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07360886
Detecção Precoce de Neuropatologias Selecionadas em Condutores de Veículos Motorizados (NeuroDrive)
Visão geral do estudo
Status
Condições
Descrição detalhada
O estudo será realizado em duas fases. Primeiro, uma coorte de participantes saudáveis será submetida a avaliação utilizando o Sistema de Teste de Viena (VTS). Posteriormente, será recrutada uma coorte clínica composta por indivíduos diagnosticados com esclerose múltipla (EM) ou doença de Parkinson (DP). Cada participante clínico completará um exame neurológico básico, incluindo a Avaliação Cognitiva de Montreal (MoCA), o Teste de Caminhada de 25 Pés (25-FWT), o Teste de Símbolos e Dígitos (SDMT) e o Teste de Encaixe de Pinos de Nove Orifícios (9-HPT). Em seguida, serão submetidos ao teste VTS.
Os doentes com DP serão classificados de acordo com a escala de Hoehn e Yahr, enquanto os com EM serão classificados utilizando a Escala Expandida do Estado de Incapacidade (EDSS). O objetivo é determinar quais testes clínicos de fácil acesso apresentam a correlação mais forte com os resultados do VTS, identificando assim marcadores fiáveis que possam ser incorporados nas avaliações médicas padrão de condutores.
Na segunda fase, achados paraclínicos obtidos fora do âmbito deste estudo serão utilizados para reforçar a base de evidências. Em última análise, o projeto pretende propor uma equação de risco na forma de uma calculadora prática que os médicos possam utilizar ao avaliar a aptidão de um doente para conduzir. Um resultado adicional esperado é o desenvolvimento de intervenções direcionadas de treino cognitivo e motor para ajudar os condutores com neuropatologias a manter ou melhorar as suas capacidades de condução segura.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Ladislav Stanke, Ph.D.
- Número de telefone: +420 588 443 713
- E-mail: Ladislav.Stanke@fnol.cz
Estude backup de contato
- Nome: Dalibor Zimek, M.D.
- Número de telefone: +420 702 048 036
- E-mail: Dalibor.Zimek@fnol.cz
Locais de estudo
-
-
Olomouc Region
-
Olomouc, Olomouc Region, Tcheca, 779 00
- Recrutamento
- University Hospital Olomouc
-
Contato:
- Ladislav Stanke, Ph.D.
- Número de telefone: +420 588 443 713
- E-mail: Ladislav.Stanke@fnol.cz
-
Contato:
- Dalibor Zimek, M.D.
- Número de telefone: +420 702 048 036
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
Descrição
Critérios de Inclusão:
- Pessoa após assinatura do consentimento informado.
- Após cumprir os critérios de diagnóstico válidos para o diagnóstico neurológico em questão.
- Possuir carta de condução válida e prova de condução ativa.
- Limite de idade 18 - 85 anos.
Critérios de Exclusão:
- Diagnóstico comprovado de demência com base num exame psicológico atual (MMSE 24 pontos ou menos).
- Diagnóstico de doença ou condição que, de acordo com a Lei Checa nº 277/2004 Coll., sobre aptidão médica para conduzir veículos motorizados, conforme alterada (especialmente Lei nº 204/2025 Coll.), impeça ou limite significativamente a capacidade de conduzir um veículo motorizado com segurança (por exemplo, demência, epilepsia, perturbações graves da consciência).
- Idade inferior a 18 anos.
- Idade superior a 85 anos.
- Na segunda coorte (doentes com Esclerose Múltipla), recaída comprovada e tratada nas últimas 6 semanas antes da inclusão no estudo.
- Na coorte de EM, EDSS atual > 6,5 pontos.
- Para a coorte de DP, pontuação atual na escala de Hoehn e Yahr superior ou igual a 4.
- Para ambas as coortes, evidência de deterioração parainfecciosa demonstrada por testes laboratoriais.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
|---|
|
Parkinson disease cohort
PD patients cohort will consist of 100 patients with parkinson disease aged between 18-85 years, with, with a balanced sex distribution to ensure representativeness and reduce gender bias.
The target sample size (N = 100) has been chosen to provide adequate statistical power to detect moderate to strong correlations between clinical and paraclinical measures, it is intended to acquire a regular distribution across all age groups .
Participants with premorbid cognitive impairment or those not clinically stable during the study period will be excluded, also participants with a Hoehn and Yahr stage greater than 4 will be excluded.
|
|
Multiple sclerosis cohort
Multiple sclerosis patient cohort will consist of 100 patients with multiple sclerosis.
aged between 18-85 years, with, with a balanced sex distribution to ensure representativeness and reduce gender bias.
The target sample size (N = 100) has been chosen to provide adequate statistical power to detect moderate to strong correlations between clinical and paraclinical measures, it is intended to acquire a regular distribution across all age groups.
Participants with premorbid cognitive impairment or those not clinically stable during the study period will be excluded also an Expanded Disability Status Scale (EDSS) score above 6.5 will serve as an exclusion criterion.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Vienna Test Systems (VTS) - Determination Test (DT)
Prazo: Day 1
|
Vienna Test System (VTS) - Determination Test (DT). A computerized test of attention, stress tolerance, and psychomotor reactivity under complex conditions. Participants are presented with rapidly changing visual and auditory stimuli (e.g., colored lights, acoustic signals) and must respond as quickly as possible using multiple response keys or pedals. Scoring: outcomes include mean and median reaction time (ms), number of correct responses, omission errors (missed stimuli), commission errors (incorrect responses), and measures of performance stability across the task. Faster, more accurate, and stable performance indicates better attentional control and stress tolerance. Administration: conducted in a quiet environment with standardized VTS hardware and software. Trained staff provide uniform instructions and monitor performance. |
Day 1
|
|
Vienna Test Systems (VTS) - Reaction Test (RT)
Prazo: Day 1
|
Vienna Test System (VTS) - Reaction Test (RT). A computerized assessment of simple and choice reaction time measuring perceptual speed and motor response. Participants are presented with visual and/or auditory stimuli and instructed to respond as quickly as possible by pressing a button (simple RT) or selecting the correct response among multiple options (choice RT). Scoring: main outcomes include mean reaction time (ms), number of correct responses, and error rates. Faster and more accurate responses indicate better psychomotor speed and attention. Separate scores are calculated for simple and choice conditions. Administration: conducted individually in a quiet, distraction-free environment using standardized VTS hardware and software. Trained staff provide standardized instructions and supervise. |
Day 1
|
|
Vienna Test Systems (VTS) - Response inhibition (INHIB)
Prazo: Day 1
|
Vienna Test System (VTS) - Response Inhibition (INHIB). A computerized go/no-go paradigm measuring impulse control and inhibitory executive function. Participants are presented with a continuous sequence of visual stimuli on screen. They are instructed to respond via button press to "go" stimuli and withhold responses to "no-go" stimuli. Scoring: main outcomes include reaction time to go-stimuli, number of correct responses (hits), commission errors (responses to no-go stimuli), and omission errors (missed go-stimuli). Higher accuracy with fewer commission errors reflects better inhibitory control. Administration: conducted individually in a distraction-free environment using standardized VTS software and response panel. Trained staff provide instructions and supervise performance. |
Day 1
|
|
Vienna Test Systems (VTS) - Vigilance/Sustained attention (WAFV) - Short version
Prazo: Day 1
|
Vienna Test System (VTS) - Vigilance/Sustained Attention (WAFV). A computerized test measuring sustained attention and vigilance. Participants monitor a continuous sequence of simple visual stimuli (e.g., small changes in geometric figures) presented at regular intervals. They are instructed to respond via button press whenever a predefined critical stimulus appears. Scoring: main outcomes include number of correct detections (hits), omissions (missed targets), false alarms (incorrect responses), and reaction times. Higher hits and faster, stable reaction times indicate better vigilance; higher omissions or false alarms indicate poorer sustained attention. Administration: conducted individually in a distraction-free environment using the standardized VTS software and response panel. Trained staff provide instructions and supervise. |
Day 1
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Montreal Cognitive Assessment (MoCA)
Prazo: Day 1
|
Montreal Cognitive Assessment (MoCA). A clinician-administered screening tool for mild cognitive impairment covering multiple domains: attention, concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. The test consists of 30 items with a maximum total score of 30; higher scores = better cognition. A score of 26 or above is considered normal. If the participant has ≤12 years of formal education, +1 point is added. Administration: conducted face-to-face in a quiet environment by trained staff using validated language versions; completion requires ~10-15 minutes. Outcomes: total score and change from baseline. |
Day 1
|
|
25-Foot Walk Test (25-FWT)
Prazo: Day 1
|
25-Foot Walk Test (25-FWT). A quantitative measure of ambulatory function and walking speed. Participants are instructed to walk 25 feet (7.62 m) as quickly and safely as possible. Two trials are performed, typically with a short rest interval, and the average time (in seconds) is recorded using a stopwatch. Lower times = better mobility. Use of customary assistive devices (e.g., cane, walker) is permitted and documented. Administration: conducted in a straight, unobstructed corridor with clearly marked start and finish lines. Trained staff provide standardized instructions and supervise for safety. Completion typically requires ~5 minutes. Outcomes: average time to walk 25 feet (7.62 meters), ability to complete the test, and change from baseline. |
Day 1
|
|
Symbol Digit Modalities Test (SDMT)
Prazo: Day 1
|
Symbol Digit Modalities Test (SDMT). A brief neurocognitive test of attention, processing speed, and visual scanning. Participants are shown a key pairing nine symbols with digits 1-9. Using this key, they write or orally state the digit corresponding to each symbol in a randomized sequence presented on the test form. Scoring: the number of correct substitutions completed in 90 seconds is counted. Higher scores = better cognitive performance. Errors are recorded but not included in the raw score. Written and oral versions are available; the same mode is used across visits for consistency. Administration: conducted in a quiet environment with standardized instructions, requiring ~5 minutes. Staff monitor to ensure task adherence. Outcomes: total correct substitutions and standard deviation change from the normal value. |
Day 1
|
|
Nine-Hole Peg Test (9-HPT)
Prazo: Day 1
|
Nine-Hole Peg Test (9-HPT). A standardized test of finger dexterity and fine motor function. Participants are instructed to place nine pegs into nine holes on a board, one at a time, as quickly as possible, and then remove them. Each hand is tested separately, typically with the dominant hand first, followed by the non-dominant hand. Scoring: performance time (in seconds) for each hand is recorded with a stopwatch. Lower times = better dexterity. Two consecutive trials per hand are averaged. If a peg is dropped, the participant retrieves it and continues. Administration: administered in a quiet environment by trained staff using standardized instructions. Completion time is usually 3-5 minutes for both hands. Outcomes: mean completion time for each hand and change from baseline. |
Day 1
|
|
Benton Visual Retention Test (BVRT)
Prazo: Day 1
|
A neuropsychological assessment of visual memory, perception, and visuoconstructive ability. Participants are shown a series of 10 geometric designs, each displayed for 10 seconds, and then asked to reproduce the design from memory using paper and pencil (Administration A). Alternate forms may be used to minimize practice effects. Scoring: each reproduction is scored for number correct (maximum = 10) and for errors (e.g., omissions, distortions, rotations, perseverations, misplacements). Higher correct scores indicate better performance, while higher error counts indicate impairment. Administration: conducted individually in a quiet setting by trained staff; typical completion ~15 minutes. Outcomes: total correct responses, total errors, and change from baseline. |
Day 1
|
|
The Big Five Inventory-2 Short Form (BFI-2-S)
Prazo: Day 1
|
Big Five Inventory-2 Short Form (BFI-2-S). A 30-item self-report assessing five personality domains: Extraversion, Agreeableness, Conscientiousness, Negative Emotionality, and Open-Mindedness. Items are rated on a 5-point Likert scale (1 = disagree strongly to 5 = agree strongly). For each domain, compute the mean of its 6 items after applying the manual's reverse-keying rules; higher scores = more of that trait. No total score is used. Administration: validated language version via paper or secure ePRO; typical completion ~5-7 min. Staff provide standardized instructions and check completeness. Outcomes: domain scores (1-5) and change from baseline. Timing: baseline and follow-ups within ±3 days of the visit window. |
Day 1
|
|
Epworth Sleepiness Scale (ESS)
Prazo: Day 1
|
An 8-item self-report of daytime sleepiness. Participants rate their chance of dozing in common situations from 0 (would never doze) to 3 (high chance). Total score = sum of items (range 0-24; higher = worse sleepiness). Severity bands: 0-5 normal, 6-10 higher-than-normal, 11-12 mild, 13-15 moderate, 16-24 severe. Administration: validated language version via paper or secure ePRO; typical completion ~2-3 min. Staff provide standardized instructions and check completeness before scoring. Outcomes: total score; change from baseline; response = ≥3-point reduction from baseline; remission = score ≤10. |
Day 1
|
|
Beck's Depression Inventory (BDI-II)
Prazo: Day 1
|
A 21-item self-report questionnaire assessing depressive symptoms over the past 2 weeks, including today.
Each item is rated 0-3; total score ranges 0-63, with higher scores indicating more severe depression.
Severity categories: 0-13 minimal, 14-19 mild, 20-28 moderate, 29-63 severe.
The BDI-II is administered in validated language versions on paper or secure ePRO, requiring ~5-10 minutes.
Staff provide standardized instructions and check completeness.
Outcomes include total score, change from baseline, response (≥50% reduction from baseline), and remission (score ≤13).
|
Day 1
|
|
Driving experience self-evaluation questionnaire
Prazo: Day 1
|
This self-report questionnaire captures recent driving exposure and perceived difficulties over the past month.
Items use 7-point Likert scales anchored "Never (1)" to "Every drive (7)".
Content includes deliberate avoidance of challenging conditions (night driving, heavy traffic, bad weather, highways, unfamiliar routes), fatigue while driving, uncertainty in traffic situations (e.g., speed limits, lane selection, right of way), perceived complexity/overload, inattention, vehicle-control errors (e.g., wrong gear, pedal mix-ups), oversight errors (e.g., missed lights/signs, failure to check mirrors), warnings from other road users, risk-taking, traffic-rule violations, and emotional arousal during driving.
A brief exposure module records typical driving frequency, lifetime kilometers, and the frequency of driving in specific conditions.
Higher scores indicate more frequent difficulties; the primary metric is the mean item score (1-7).
|
Day 1
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Sinucleinopatias
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Doenças autoimunes
- Doenças do sistema imunológico
- Doenças Autoimunes Desmielinizantes, SNC
- Doenças Autoimunes do Sistema Nervoso
- Doenças Desmielinizantes
- Doenças Neurodegenerativas
- Distúrbios do Movimento
- Distúrbios parkinsonianos
- Doenças dos Gânglios da Base
- Esclerose múltipla
- Doença de Parkinson
Outros números de identificação do estudo
- OP JAK ITI VZ 1
- CZ.02.01.01/00/23_021/0008829 (Número de outro subsídio/financiamento: Operational Programme Jan Ámos Komenský financed by the European Union (EU) and the State Budget of Czech Republic)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .